HC Wainwright & Co. Affirms Buy Rating for Immunocore Holdings, Keeps $100 Price Target Intact

Written by Emily J. Thompson, Senior Investment Analyst

Source: Benzinga

Updated: Oct 22 2025

0mins

IMCR+1.54%

Should l Buy IMCR?

Source: Benzinga

Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders, helping them stay informed and make timely decisions in the stock market.
Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters, enhancing the trading experience for its users.
Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, indicating a robust network for sharing market intelligence.
Market Winning Tools: Benzinga Pro is designed to equip traders with the tools and information necessary to succeed in the markets daily.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy IMCR?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on IMCR

Wall Street analysts forecast IMCR stock price to rise

9 Analyst Rating

7 Buy

2 Hold

0 Sell

Strong Buy

Current: 31.790

Low

37.00

Averages

64.56

High

100.00

Current: 31.790

Low

37.00

Averages

64.56

High

100.00

Morgan Stanley

Sean Laaman

Equal Weight

maintain

$36 -> $40

2026-01-08

Reason

Morgan Stanley

Sean Laaman

Price Target

$36 -> $40

AI Analysis

2026-01-08

maintain

Equal Weight

Reason

Morgan Stanley analyst Sean Laaman raised the firm's price target on Immunocore to $40 from $36 and keeps an Equal Weight rating on the shares. The firm sees a continuation of U.S. small-to-mid cap biotech's outperformance in 2026 as commercial names transition from "capital consumers to producers" and Large Cap Biopharma faces a looming patent cliff, the analyst tells investors in an outlook note for the group.

UBS

Sell -> Buy

upgrade

$24 -> $55

2026-01-07

Reason

UBS

Price Target

$24 -> $55

2026-01-07

upgrade

Sell -> Buy

Reason

UBS upgraded Immunocore (IMCR) to Buy from Sell with a price target of $55, up from $24, as the analyst initiated or assumed coverage on 22 small-to-mid cap biotech names. After a rough period, biotech fundamentals are now inflecting, contends the analyst, who expects investor confidence to recover and sees this positioning biotech for strong performance in 2026. Among the group, top picks include Apogee Therapeutics (APGE), Cogent Biosciences (COGT), Kodiak Sciences (KOD), Ideaya Biosciences (IDYA), Inventiva (IVA), SAB Biotherapeutics (SABS) and Ventyx Biosciences (VTYX), which the analyst highlights as having key upcoming catalysts, de-risked best-in-class portfolios, strong data, and broader pipelines.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for IMCR

Unlock Now

About IMCR

Immunocore Holdings plc is a United Kingdom-based commercial-stage biotechnology company. The Company is engaged in the development of TCR bispecific immunotherapies, ImmTAX, which immunes mobilizing monoclonal TCRs against X disease, designed to treat a range of diseases, including cancer, autoimmune and infectious disease. The Company has a pipeline of clinical-stage programs in oncology and infectious diseases, as well as numerous pre-clinical projects. Its lead product, KIMMTRAK, is a TCR therapeutic for the treatment of patients with unresectable or metastatic uveal melanoma (mUM), in the United States, European Union, Canada, Australia and the United Kingdom. Its pipeline products include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-M113V, IMC-I109V, IMC-S118AI, and IMC-U120AI, among others. Its clinical programs are being conducted with patients with a range of cancers including melanoma, ovarian, lung, colorectal and others.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Immunocore Announces R&D Leadership Changes

Jan 30 2026Newsfilter

Executive Departure: Immunocore announced that Executive Vice President of R&D David Berman will leave the company on February 27, 2026, to take a role at another biotech firm, indicating a significant leadership transition for the company.
Internal Promotions: The company is promoting current Chief Medical Officer Mohammed Dar and Head of Regulatory Sciences Mark Moyer to Executive Vice President roles, with expanded responsibilities for clinical development and regulatory strategies, aiming to enhance R&D efficiency by leveraging the existing leadership team.
R&D Achievements: Dar has led clinical development since 2019, successfully advancing KIMMTRAK to regulatory approval, which is now approved in 39 countries, showcasing the company's strong capabilities in oncology immunotherapy.
Strategic Commitment: CEO Bahija Jallal expressed confidence in the R&D team despite the executive changes, committing to continue advancing clinical programs to meet patient needs for transformative therapies.

Immunocore to Showcase at Upcoming Investor Events

Nov 10 2025Newsfilter

Company Overview: Immunocore Holdings plc is a biotechnology company focused on developing immunomodulating medicines for cancer, infectious diseases, and autoimmune diseases, utilizing its ImmTAX platform for TCR bispecific immunotherapies.
Upcoming Conferences: The company will participate in the Guggenheim 2nd Annual Healthcare Innovation Conference on November 11, 2025, and the Jefferies London Healthcare Conference on November 19, 2025, with live webcasts available on their website.
Product Highlight: Immunocore's leading oncology therapy, KIMMTRAK, is approved for treating HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma in several countries, including the US and EU.
Contact Information: For inquiries, Immunocore provides contact details for communications and investor relations, including email addresses and phone numbers.